Inflammatory cytokine pathways – indirect transcriptional modulation

Inflammatory cytokine pathways – indirect transcriptional modulation refers to a therapeutic strategy aimed at reducing the production of pro-inflammatory mediators by targeting the intracellular machinery responsible for their gene expression. Unlike monoclonal antibodies that neutralize specific cytokines (e.g., TNF-alpha or IL-6) in the extracellular space, this approach utilizes small molecules to inhibit signaling cascades such as the JAK/STAT or NF-κB pathways, or to interfere with epigenetic "readers" like BET proteins that facilitate the transcription of inflammatory genes (O'Shea et al., 2013; Belkina & Denis, 2012). By modulating these central nodes, a single drug can simultaneously downregulate multiple cytokines, offering a broader anti-inflammatory effect. This strategy is particularly relevant in complex autoimmune and autoinflammatory diseases where multiple redundant pathways contribute to pathogenesis (Schett et al., 2013). However, because these pathways often govern essential cellular processes beyond inflammation, such as hematopoiesis and antiviral defense, indirect modulation carries risks of systemic side effects and immunosuppression. Consequently, this "target" is better understood as a pharmacological mechanism of action involving various discrete molecular targets like kinases and epigenetic readers.

Other names

Indirect cytokine inhibitionTranscriptional regulation of inflammatory mediatorsSignaling-mediated cytokine modulationTranscriptional control of cytokines

Inhibition of intracellular signaling cascades (e.g., JAK/STAT) or epigenetic regulators (e.g., BET proteins) to prevent the transcription of pro-inflammatory cytokine genes.